C9orf134 Activators

Chemical activators of C9orf134 employ various molecular mechanisms to enhance its phosphorylation state, ultimately leading to its activation. Forskolin, through its ability to activate adenylate cyclase, increases intracellular cAMP levels. Elevated cAMP then activates protein kinase A (PKA), which is known for phosphorylating serine and threonine residues on specific proteins, including C9orf134. Similarly, Dibutyryl cyclic AMP (dbcAMP), a synthetic analog of cAMP, also activates PKA, facilitating the phosphorylation and consequent activation of C9orf134. Phorbol 12-myristate 13-acetate (PMA), on the other hand, directly stimulates protein kinase C (PKC), which phosphorylates a broad range of proteins. The activation of PKC by PMA can lead to the phosphorylation of C9orf134. 4-Phorbol 12,13-didecanoate, another PKC activator, functions similarly to PMA, promoting the phosphorylation and activation of C9orf134.

Ionomycin acts by increasing intracellular calcium levels, which then activates calcium-dependent protein kinases capable of phosphorylating C9orf134. Thapsigargin follows a related pathway by inhibiting the SERCA calcium pumps, thereby raising cytosolic calcium levels and activating calcium-dependent kinases that may target C9orf134. Zinc Pyrithione also elevates intracellular calcium, but through the mobilization of internal stores, supporting the activation of calcium-dependent pathways that phosphorylate C9orf134. Anisomycin stimulates the MAPK/ERK pathway, a cascade that culminates in the activation of kinases that can phosphorylate C9orf134. Epigallocatechin Gallate (EGCG) influences various kinases and signaling pathways, potentially leading to the activation of C9orf134 through phosphorylation. Lastly, Okadaic Acid and Calyculin A inhibit protein phosphatases 1 and 2A, leading to an increase in the phosphorylated state of proteins including C9orf134 due to reduced dephosphorylation, thereby maintaining C9orf134 in an active state. Bisindolylmaleimide I, although primarily a PKC inhibitor, under certain conditions can paradoxically activate specific PKC isoforms, which might contribute to the phosphorylation and activation of C9orf134.